Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 02, 2023

Overall Survival With Sacituzumab Govitecan in Patients With Pretreated, Endocrine-Resistant, HR+/HER2− Metastatic Breast Cancer

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
Lancet 2023 Aug 23;[EPub Ahead of Print], HS Rugo, A Bardia, F Marmé, J Cortés, P Schmid, D Loirat, O Trédan, E Ciruelos, F Dalenc, P Gómez Pardo, KL Jhaveri, R Delaney, T Valdez, H Wang, M Motwani, OK Yoon, W Verret, SM Tolaney

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading